Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intra-Cellular Therapies

131.87
+0.0000
Volume:- -
Turnover:- -
Market Cap:14.02B
PE:-182.12
High:131.87
Open:131.87
Low:131.87
Close:131.87
Loading ...
OverviewCompanyNewsFilings

FACTBOX-Drugmakers rush to sign deals on first day of industry conference

Reuters
·
14 Jan

Hold Rating Reiterated for Intra-Cellular Therapies Amid Johnson & Johnson Acquisition at $132 per Share

TIPRANKS
·
14 Jan

Top Midday Stories: Moderna Shares Fall After 2025 Revenue Guidance Cut; Cleveland-Cliffs Reportedly Teams Up With Nucor in Potential Bid for US Steel

MT Newswires Live
·
14 Jan

ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz

Zacks
·
14 Jan

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- WSJ

Dow Jones
·
14 Jan

These Stocks Are Moving the Most Today: Nvidia, Tesla, Moderna, Intra-Cellular Therapies, JPMorgan, U.S. Steel, Abercrombie, and More -- Barrons.com

Dow Jones
·
13 Jan

Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal -- Barrons.com

Dow Jones
·
13 Jan

Intra-Cellular Therapies Up Over 34%, on Track for Record High Close -- Data Talk

Dow Jones
·
13 Jan

Intra-Cellular Therapies Cut to Hold From Buy by Needham

Dow Jones
·
13 Jan

J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders

Associated Press Finance
·
13 Jan

Intra-Cellular Therapies Soars 32% With Johnson & Johnson's $14.6B Acquisition

GuruFocus.com
·
13 Jan

Johnson & Johnson Makes Biopharmaceutical Splash with $14.6B Intra-Cellular Deal

Design & Development Today
·
13 Jan

Intra-Cellular downgraded to Hold from Buy at Needham

TIPRANKS
·
13 Jan

Intra-Cellular Therapies Inc : Needham Cuts to Hold From Buy

THOMSON REUTERS
·
13 Jan

Biopharmaceutical Companies Intra-Cellular and Sage Surge 34% As Drug Giants Make Acquisition Bids

Tiger Newspress
·
13 Jan

Morgan Stanley Downgrades Intra-Cellular Therapies to Equalweight From Overweight, $132 Price Target

MT Newswires Live
·
13 Jan

Hold Rating on JNJ Amid Uncertainty over Intra-Cellular Therapies Acquisition Impact

TIPRANKS
·
13 Jan

Intra-Cellular Therapies Shares Jump 34.6% After J&J to Acquire Co in $14.6 Bln Deal

THOMSON REUTERS
·
13 Jan

Sector Update: Health Care Stocks Mixed Pre-Bell Monday

MT Newswires Live
·
13 Jan

Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B

Investopedia
·
13 Jan
More